Disc Medicine, Inc. (NASDAQ:IRON) Stock Has Consensus Price Target of $124.18 According to Brokerages

Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) has been assigned an average rating of “Moderate Buy” from the fourteen research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $124.18.

IRON has been the topic of a number of recent research reports. Truist Financial upped their target price on shares of Disc Medicine from $83.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, October 19th. HC Wainwright boosted their price objective on shares of Disc Medicine from $120.00 to $127.00 and gave the company a “buy” rating in a report on Friday, November 6th. Wedbush increased their target price on Disc Medicine from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, October 19th. Jefferies Financial Group reissued a “buy” rating and set a $149.00 price objective on shares of Disc Medicine in a research report on Wednesday, October 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research report on Thursday, October 15th.

Get Our Latest Analysis on IRON

Insiders Place Their Bets

In related news, COO Jonathan Yu sold 8,796 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total transaction of $731,123.52. Following the completion of the transaction, the chief operating officer owned 54,324 shares in the company, valued at approximately $4,515,410.88. This represents a 13.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John D. Quisel sold 33,000 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $79.15, for a total transaction of $2,611,950.00. Following the transaction, the chief executive officer directly owned 226,064 shares of the company’s stock, valued at $17,892,965.60. The trade was a 12.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 183,277 shares of company stock worth $14,489,009. 3.76% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Disc Medicine

Several institutional investors have recently added to or reduced their stakes in IRON. State of Wyoming bought a new position in Disc Medicine during the second quarter valued at $25,000. Allworth Financial LP purchased a new stake in shares of Disc Medicine in the second quarter valued at approximately $46,000. Sterling Capital Management LLC increased its position in Disc Medicine by 842.4% during the 3rd quarter. Sterling Capital Management LLC now owns 933 shares of the company’s stock valued at $61,000 after purchasing an additional 834 shares during the period. Nykredit A S purchased a new position in shares of Disc Medicine in the 2nd quarter valued at $103,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new position in Disc Medicine in the third quarter worth about $119,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Trading Down 3.9%

Shares of NASDAQ IRON traded down $3.23 during mid-day trading on Tuesday, hitting $80.00. The stock had a trading volume of 779,945 shares, compared to its average volume of 1,702,055. The company has a debt-to-equity ratio of 0.10, a quick ratio of 24.14 and a current ratio of 20.30. Disc Medicine has a 1 year low of $40.00 and a 1 year high of $99.50. The business has a 50 day moving average price of $71.60 and a two-hundred day moving average price of $71.07. The firm has a market cap of $3.64 billion, a P/E ratio of -12.62 and a beta of 0.96.

Disc Medicine (NASDAQ:IRON – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.53) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.10. On average, equities analysts anticipate that Disc Medicine will post -6.20 EPS for the current fiscal year.

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function. The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.

See Also

Analyst Recommendations for Disc Medicine (NASDAQ:IRON)

Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.